Mainz Biomed B.V. Logo

Mainz Biomed B.V.

MYNZ

(0.2)
Stock Price

6,97 USD

-164.26% ROA

-498.52% ROE

-0.31x PER

Market Cap.

6.347.107,00 USD

228.39% DER

0% Yield

-3057.88% NPM

Mainz Biomed B.V. Stock Analysis

Mainz Biomed B.V. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Mainz Biomed B.V. Fundamental Stock Analysis
# Analysis Rating
1 Graham Number

The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity.

2 ROE

The stock's ROE indicates a negative return (-273498.4%) on shareholders' equity, suggesting poor financial performance.

3 ROA

The stock's ROA (-168381.72%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

4 PBV

The stock's elevated P/BV ratio (3.49x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

5 DER

The company has a high debt to equity ratio (165%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Mainz Biomed B.V. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Mainz Biomed B.V. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Sell
4 Stoch RSI Buy

Mainz Biomed B.V. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Mainz Biomed B.V. Revenue
Year Revenue Growth
2019 281.393
2020 493.565 42.99%
2021 577.348 14.51%
2022 529.877 -8.96%
2023 859.044 38.32%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Mainz Biomed B.V. Research and Development Expenses
Year Research and Development Expenses Growth
2019 250.316
2020 311.851 19.73%
2021 466.689 33.18%
2022 3.660.495 87.25%
2023 7.996.900 54.23%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Mainz Biomed B.V. General and Administrative Expenses
Year General and Administrative Expenses Growth
2019 388.785
2020 347.994 -11.72%
2021 8.453.562 95.88%
2022 17.831.768 52.59%
2023 14.123.444 -26.26%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Mainz Biomed B.V. EBITDA
Year EBITDA Growth
2019 -682.666
2020 -265.349 -157.27%
2021 -9.266.319 97.14%
2022 -25.652.825 63.88%
2023 -21.748.048 -17.95%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Mainz Biomed B.V. Gross Profit
Year Gross Profit Growth
2019 -61.271
2020 123.085 149.78%
2021 177.622 30.7%
2022 182.151 2.49%
2023 538.936 66.2%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Mainz Biomed B.V. Net Profit
Year Net Profit Growth
2019 -1.174.766
2020 -886.177 -32.57%
2021 -12.072.280 92.66%
2022 -26.452.725 54.36%
2023 -20.733.308 -27.59%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Mainz Biomed B.V. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2019 0
2020 0 0%
2021 -2 100%
2022 -2 0%
2023 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Mainz Biomed B.V. Free Cashflow
Year Free Cashflow Growth
2019 -416.495
2020 -478.422 12.94%
2021 -3.237.029 85.22%
2022 -15.428.073 79.02%
2023 -4.916.995 -213.77%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Mainz Biomed B.V. Operating Cashflow
Year Operating Cashflow Growth
2019 -416.495
2020 -468.737 11.15%
2021 -3.220.324 85.44%
2022 -14.769.590 78.2%
2023 -4.655.187 -217.27%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Mainz Biomed B.V. Capital Expenditure
Year Capital Expenditure Growth
2019 0
2020 9.685 100%
2021 16.705 42.02%
2022 658.483 97.46%
2023 261.808 -151.51%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Mainz Biomed B.V. Equity
Year Equity Growth
2019 -1.950.296
2020 -2.741.555 28.86%
2021 6.361.155 143.1%
2022 14.096.067 54.87%
2023 3.249.226 -333.83%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Mainz Biomed B.V. Assets
Year Assets Growth
2019 715.959
2020 673.270 -6.34%
2021 10.040.795 93.29%
2022 20.241.003 50.39%
2023 15.409.028 -31.36%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Mainz Biomed B.V. Liabilities
Year Liabilities Growth
2019 2.666.255
2020 3.414.825 21.92%
2021 3.679.640 7.2%
2022 6.144.936 40.12%
2023 12.159.802 49.47%

Mainz Biomed B.V. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.03
Net Income per Share
-0.93
Price to Earning Ratio
-0.31x
Price To Sales Ratio
9.83x
POCF Ratio
-0.38
PFCF Ratio
-0.38
Price to Book Ratio
1.89
EV to Sales
10.38
EV Over EBITDA
-0.36
EV to Operating CashFlow
-0.41
EV to FreeCashFlow
-0.4
Earnings Yield
-3.22
FreeCashFlow Yield
-2.64
Market Cap
0,01 Bil.
Enterprise Value
0,01 Bil.
Graham Number
1.79
Graham NetNet
-0.21

Income Statement Metrics

Net Income per Share
-0.93
Income Quality
0.82
ROE
-4.99
Return On Assets
-1.28
Return On Capital Employed
-3.27
Net Income per EBT
1
EBT Per Ebit
0.98
Ebit per Revenue
-31.23
Effective Tax Rate
-0.1

Margins

Sales, General, & Administrative to Revenue
14.07
Research & Developement to Revenue
11.36
Stock Based Compensation to Revenue
6.21
Gross Profit Margin
0.57
Operating Profit Margin
-31.23
Pretax Profit Margin
-30.58
Net Profit Margin
-30.58

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.77
Free CashFlow per Share
-0.79
Capex to Operating CashFlow
-0.03
Capex to Revenue
0.77
Capex to Depreciation
0.86
Return on Invested Capital
-2.08
Return on Tangible Assets
-1.64
Days Sales Outstanding
200.5
Days Payables Outstanding
3135.13
Days of Inventory on Hand
815.48
Receivables Turnover
1.82
Payables Turnover
0.12
Inventory Turnover
0.45
Capex per Share
0.02

Balance Sheet

Cash per Share
0,33
Book Value per Share
0,15
Tangible Book Value per Share
-0.01
Shareholders Equity per Share
0.15
Interest Debt per Share
0.35
Debt to Equity
2.28
Debt to Assets
0.48
Net Debt to EBITDA
-0.02
Current Ratio
0.97
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
6171984
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.22
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
553613
Debt to Market Cap
1.17

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Mainz Biomed B.V. Dividends
Year Dividends Growth

Mainz Biomed B.V. Profile

About Mainz Biomed B.V.

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

CEO
Mr. Guido Baechler
Employee
65
Address
Robert Koch Strasse 50
Mainz, 55129

Mainz Biomed B.V. Executives & BODs

Mainz Biomed B.V. Executives & BODs
# Name Age
1 Mr. William J. Caragol
Chief Financial Officer
70
2 Mr. Guido Baechler
Chief Executive Officer & Executive Director
70
3 Dr. Christopher Von Torne P.M.P., Ph.D.
Chief Operating Officer
70
4 Dr. Frank Krieg-Schneider
Chief Technology Officer
70
5 Dr. Moritz Eidens Ph.D.
Chief Science Officer & Executive Director
70
6 Stefan Erlach
Head of Human Resources
70
7 Mr. Philipp Freese
Chief Business Officer
70

Mainz Biomed B.V. Competitors